Arch Therapeutics, Inc. reported earnings results for the second quarter and six months ended March 31, 2024. For the second quarter, the company reported sales was USD 0.031866 million compared to USD 0.016654 million a year ago. Net loss was USD 1.47 million compared to USD 0.902477 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.71 a year ago. Diluted loss per share from continuing operations was USD 0.33 compared to USD 0.71 a year ago.
For the six months, sales was USD 0.077733 million compared to USD 0.022914 million a year ago. Net loss was USD 4.15 million compared to USD 2.7 million a year ago. Basic loss per share from continuing operations was USD 0.9 compared to USD 2.15 a year ago. Diluted loss per share from continuing operations was USD 0.9 compared to USD 2.15 a year ago.